ATM and breast carcinoma: XRCC1 loss amplifies the sensitivity of pancreatic cancer cells to β-lapachone [40], triple negative breast cancers to the ATM, ATR, and Wee1 inhibitors [41], liver adenocarcinoma HepG2 to γ rays [42], and breast cancer cells to cisplatin, camptothecin, and MMS [43].